Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.36 |
| ▸ | CTSB | P07858 | 10/20 | 0.36 |
| ▸ | CTSL | P07711 | 9/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.32 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 5/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571017 | 0.76 | CTSS (0.34) | CTSSCTSBCTSLCTSK | |
| SCHEMBL5438728 | 0.76 | CA12 (0.34) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL6062055 | 0.75 | CTSS (0.43) | CTSSCTSBCTSLCTSK | |
| SCHEMBL7666708 | 0.75 | CTSS (0.34) | CTSSCTSBCTSL | |
| SCHEMBL5445593 | 0.75 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL5445291 | 0.74 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL6061996 | 0.73 | CTSS (0.40) | CTSSCTSBCTSLALDH1A1GAA | |
| SCHEMBL6061716 | 0.71 | L3MBTL1 (0.32) | ALDH1A1KDM4EGAAMAP3K7TAB1 | |
| SCHEMBL7666715 | 0.71 | CTSS (0.44) | CTSSCTSBCTSLCTSK | |
| SCHEMBL6063311 | 0.70 | CTSS (0.49) | CTSSCTSBCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694357-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058348-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | CTSS 1/4885CTSB 2/4885CTSL 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.